http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이영복(Y.B. Lee),김장묵(J.M. Kim),임익헌(I.H. Lim),류호선(H.S. Ryu),송승호(S.H. Song) 전력전자학회 2003 전력전자학술대회 논문집 Vol.2003 No.7(2)
The conventional analog-based firing circuit can be Implemented by comparing a linearly decreasing periodic sawtooth waveform synchronized to the ac line, With a voltage corresponding to the desired converter delay angle This circuit requires a large number of components (resistance and capacitor) and careful adjustment of the synchronization circuity in tills paper a novel firing circuit is proposed for thyristor switch is elements The proposed circuit is Implemented on the basis of the analog cosine method using FPGA and microprocessor<br/>
인후두위산역류증(Laryngopharyngeal Reflux: LPR)의 치료에 대한 RabeprazoleSodium(Parietd)의 임상효과와 안전성 검토
정광윤,전병선,고상현,권기환,권순영,권중근,김동영,김상철,김성완,김영모,김영호,김윤환,김장묵,Jung, K.W.,Jun, B.S.,Ko, S.H.,Kwon, K.H.,Kwon, S.Y.,Kwon, J.K.,Kim,, D.Y.,Kim,, S.C.,Kim,, S.W.,Kim,, Y.M.,Kim,, Y.H.,Kim,, Y.H.,Kim,, J.M. 대한기관식도과학회 2004 大韓氣管食道科學會誌 Vol.10 No.2
Background and objective : Rabeprazole is a new generation proton pump inhibitor, which has a rapid onset after first dose, predictable efficacy in all patients regardless of CYP2C19 genotype status, and less nocturnal acid breakthrough. The aim of the study is to investigate clinical efficacy and safety of rabeprazole sodium (Pariet 10mg qd)when administered once daily to patients with laryngopharyngeal reflux(LPR) disease. Methods : Among the patients who had visited the Department of Otolaryngology, those with LPR symptoms, had undergone laryngoscopy. Symptoms and endoscopic laryngeal sings were recorded initially, at 1 month, 2 months, 3 months, and more than 3 months, All patients were evaluated for clinical efficacy on the basis of symptom scores, reflux finding score(RFS), and side effects. Results : In general, most symptom scores and RFS improved over the time. Efficacy of the Pariet on LPR-related symptoms were $63.2\%,\;77.5\%,\;78.7\%,\;and\;90.9\%$ before 4 weeks, 4 to 8 weeks, 8 to 12 weeks, and after 12 weeks respectively. Efficacy on the RFS were $61.8\%,\;78.4\%,\;82.9\%,\;and\;85.5\%$ before 4 weeks, 4 to 8 weeks, 8 to 12 weeks, and after 12 weeks respectively. Pariet was well tolerated and was associated with few drug-related side effects. Conclusion Because of its efficacy and safety, Pariet may prove to be an alternative to currently available proton pump inhibitors.